Barcelona, Spain, 5-2-2014 — /EuropaWire/ — Almirall and the representatives of the employees have signed an agreement which specifies the conditions to accomplish the company’s proposed restructuring plan in Spain, which affects 180 people and aims to balance the company’s resources to optimize the potential of its portfolio of existing and new products.
With our respect for the people finally affected by this restructuring plan, Almirall wants to thank all the parties for the efforts made to reach an agreement.
About Almirall
Almirall is a pharmaceutical Company commited to provide valueble medicines through our own R&D efforts, which exceeded 23% on sales in 2012, together with external partnerships, licences and collaborations. Through seeking innovative medicines we aim to become a relevant player in respiratory and dermatology diseases, with also a strong interest in gastroenterology and pain. With more than 3,000 employees in 22 countries, Almirall generated total revenues of 900 million in 2012.
The company was founded in 1943 and is headquartered in Barcelona, Spain. The stock is traded in the Spanish Stock Exchange (ticker: ALM).
For more information please visit: www.almirall.com
More Information:
LLORENTE&CUENCA
Ariadna Carbonell
acarbonell@llorenteycuenca.com
Phone: 00 34 93 217 22 17
Mobile: 00 34 606589136
Eva Pedrol
epedrol@llorenteycuenca.com
Phone: 00 34 93 217 22 17
Mobile: 00 34 679 269 048
Relaciones con Inversores
Jordi Molina
jordi.molina@almirall.com
Phone: 00 34 93 291 30 87
(IN BRIEF) The Lenzing Group announces the Lenzing Young Scientist Award at the Dornbirn Global…
(IN BRIEF) Josée Ouellet, Vice President of Services for Alstom in North America, has been…
(IN BRIEF) Alstom was honored with the 2024 Hydrogen Mobility Award at the 2024 Canadian…
(IN BRIEF) Alstom's Innovation Station in Stockholm has initiated a pioneering two-year collaboration with Tåg…
(IN BRIEF) Alstom's industrial site in Catalonia welcomed Spanish Minister of Transport and Sustainable Mobility,…
(IN BRIEF) Evonik has enhanced its capabilities for RESOMER® powder biomaterials at its Darmstadt site…